
Abbott Laboratories (ABT) Stock
Abbott Laboratories Chart
Company Profile
Price: $130.61
Market Cap: $226.54B
Exchange: NYSE
CEO: Mr. Robert B. Ford
Sector: Healthcare
Industry: Medical - Devices
Employees: 114.00K
Headquarters: North Chicago, IL
Website: Abbott Laboratories
Business Summary
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Abbott Laboratories News
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care
New survey shows 40% of people living with diabetes have skipped or missed a doctor's appointment due to shame or stigma1 70% of people with diabetes said supportive comments from others can significantly boost their motivation to manage their condition1 Abbott launches film that highlights challenges of living life with diabetes ABBOTT PARK, Ill., Feb. 4, 2025 /PRNewswire/ -- 'One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have diabetes.

2 Unstoppable Dividend Stocks That Will Pay You for Life
In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings.

My Best Dividend Aristocrats For February 2025
The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.

Is There More Upside For ABT Stock After A 10% Jump In A Week?
Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and $1.34, respectively.

Abbott Laboratories: Strong Q4 Results And Bullish Outlook
On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion for the three months ended December 31, 2024, up 7.2% year-on-year, driven by strong sales in the company's Medical Devices segment. Moreover, Abbott expects its revenue to grow by 7.5% to 8.5% in 2025, while its adjusted diluted EPS will be between $5.05 and $5.25, implying double-digit percentage growth year-over-year.

Abbott Laboratories Will Outperform Healthcare Stocks in 2025
The outlook and technical action suggest Abbott Laboratories NYSE: ABT will lead healthcare names like Johnson & Johnson NYSE: JNJ higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.

What Can The Dividend Kings Deliver In 2025?
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by earnings growth and dividends, with the change in P/E ratio being a detractor. I breakdown the components of total return for each Dividend King by sector to gain insights into current valuation.

Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month. The company looks set up to deliver double-digit annual adjusted diluted EPS growth for the foreseeable future. Abbott Laboratories enjoys an AA- credit rating from S&P on a stable outlook.

My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors.

Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT ) Q4 2024 Earnings Conference Call January 22, 2025 9:30 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman & Chief Executive Officer Phil Boudreau - Executive Vice President, Finance & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Josh Jennings - TD Cowen David Roman - Goldman Sachs Joanne Wuensch - Citi Danielle Antalffy - UBS Matt Miksic - Barclays Operator Good morning and thank you for standing by. Welcome to Abbott's Fourth Quarter 2024 Earnings Conference Call.

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billion Fourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1 Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2 Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5% ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024.

Abbott Laboratories Earnings
This section highlights Abbott Laboratories's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-01-22 | $1.34 | $1.34 |
Read Transcript | Q3 | 2024 | 2024-10-16 | $1.20 | $1.21 |
Read Transcript | Q2 | 2024 | 2024-07-18 | $1.10 | $1.14 |
Read Transcript | Q1 | 2024 | 2024-04-17 | $0.95 | $0.98 |
Read Transcript | Q4 | 2023 | 2024-01-23 | N/A | N/A |
Read Transcript | Q3 | 2023 | 2023-10-17 | N/A | N/A |
Read Transcript | Q2 | 2023 | 2023-07-19 | N/A | N/A |
Read Transcript | Q1 | 2023 | 2023-04-18 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Abbott Laboratories, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B |
Cost of Revenue | $17.98B | $19.14B | $18.54B | $15.00B | $13.23B |
Gross Profit | $22.13B | $24.51B | $24.54B | $19.61B | $18.67B |
Gross Profit Ratio | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% |
Research and Development Expenses | $2.74B | $2.89B | $2.74B | $2.42B | $2.44B |
General and Administrative Expenses | $- | $- | $- | $- | $- |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $10.95B | $11.25B | $11.32B | $9.70B | $9.77B |
Other Expenses | $1.97B | $2.01B | $2.05B | $2.13B | $1.94B |
Operating Expenses | $15.66B | $16.15B | $16.11B | $14.25B | $14.14B |
Cost and Expenses | $33.63B | $35.29B | $34.65B | $29.25B | $27.37B |
Interest Income | $385.00M | $183.00M | $43.00M | $46.00M | $94.00M |
Interest Expense | $637.00M | $375.00M | $490.00M | $500.00M | $576.00M |
Depreciation and Amortization | $3.24B | $3.27B | $3.54B | $3.33B | $3.01B |
EBITDA | $10.61B | $12.38B | $12.74B | $8.79B | $7.77B |
EBITDA Ratio | 26.44% | 24.50% | 24.95% | 21.94% | 20.87% |
Operating Income | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B |
Operating Income Ratio | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% |
Total Other Income Expenses Net | $186.00M | $-56.00M | $-214.00M | $-389.00M | $-455.00M |
Income Before Tax | $6.66B | $8.31B | $8.21B | $4.97B | $4.08B |
Income Before Tax Ratio | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% |
Income Tax Expense | $941.00M | $1.37B | $1.14B | $497.00M | $390.00M |
Net Income | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B |
Net Income Ratio | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% |
EPS | $3.30 | $3.94 | $3.97 | $2.52 | $2.07 |
EPS Diluted | $3.27 | $3.91 | $3.94 | $2.50 | $2.06 |
Weighted Average Shares Outstanding | 1.73B | 1.75B | 1.77B | 1.77B | 1.77B |
Weighted Average Shares Outstanding Diluted | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $10.63B | $10.38B | $9.96B | $10.24B | $10.14B | $9.98B | $9.75B | $10.09B | $10.41B | $11.26B | $11.89B | $11.47B | $10.93B | $10.22B | $10.46B | $10.70B | $8.85B | $7.33B | $7.73B | $8.31B |
Cost of Revenue | $4.70B | $4.57B | $4.42B | $4.98B | $4.61B | $4.48B | $4.31B | $4.59B | $4.63B | $4.93B | $4.99B | $4.77B | $4.42B | $4.95B | $4.40B | $4.49B | $3.97B | $3.26B | $3.28B | $3.43B |
Gross Profit | $5.94B | $5.81B | $5.54B | $5.26B | $5.54B | $5.50B | $5.43B | $5.50B | $5.78B | $6.32B | $6.91B | $6.70B | $6.50B | $5.28B | $6.05B | $6.21B | $4.89B | $4.07B | $4.45B | $4.88B |
Gross Profit Ratio | 55.83% | 55.96% | 55.64% | 51.34% | 54.60% | 55.07% | 55.74% | 54.48% | 55.53% | 56.18% | 58.07% | 58.44% | 59.53% | 51.61% | 57.91% | 58.01% | 55.20% | 55.47% | 57.53% | 58.70% |
Research and Development Expenses | $713.00M | $698.00M | $679.00M | $690.00M | $672.00M | $715.00M | $654.00M | $725.00M | $782.00M | $684.00M | $697.00M | $762.00M | $672.00M | $654.00M | $654.00M | $698.00M | $580.00M | $564.00M | $578.00M | $595.00M |
General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.55B | $- | $- | $2.55B | $2.41B |
Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $22.00M | $- | $- | $- | $- |
Selling General and Administrative Expenses | $2.90B | $2.92B | $2.94B | $2.70B | $2.60B | $2.62B | $2.62B | $2.97B | $2.73B | $2.76B | $2.79B | $3.05B | $2.77B | $2.73B | $2.78B | $2.57B | $2.30B | $2.28B | $2.55B | $2.41B |
Other Expenses | $470.00M | $-471.00M | $-472.00M | $109.00M | $83.00M | $498.00M | $491.00M | $496.00M | $498.00M | $82.00M | $512.00M | $63.00M | $74.00M | $79.00M | $61.00M | $78.00M | $46.00M | $-22.00M | $1.00M | $51.00M |
Operating Expenses | $4.08B | $4.08B | $4.09B | $3.39B | $3.80B | $3.80B | $3.82B | $4.19B | $4.01B | $3.95B | $4.00B | $4.32B | $3.96B | $3.88B | $3.95B | $3.78B | $3.39B | $3.39B | $3.69B | $3.49B |
Cost and Expenses | $8.78B | $8.65B | $8.51B | $8.38B | $8.40B | $8.28B | $8.13B | $8.79B | $8.64B | $8.88B | $8.98B | $9.09B | $8.38B | $8.83B | $8.35B | $8.27B | $7.36B | $6.66B | $6.97B | $6.92B |
Interest Income | $91.00M | $82.00M | $80.00M | $89.00M | $69.00M | $61.00M | $52.00M | $88.00M | $55.00M | $26.00M | $14.00M | $11.00M | $10.00M | $11.00M | $11.00M | $9.00M | $10.00M | $9.00M | $18.00M | $25.00M |
Interest Expense | $142.00M | $58.00M | $61.00M | $235.00M | $166.00M | $159.00M | $153.00M | $154.00M | $86.00M | $132.00M | $117.00M | $120.00M | $123.00M | $123.00M | $124.00M | $127.00M | $127.00M | $125.00M | $121.00M | $139.00M |
Depreciation and Amortization | $801.00M | $805.00M | $805.00M | $813.00M | $824.00M | $800.00M | $806.00M | $807.00M | $815.00M | $822.00M | $823.00M | $883.00M | $847.00M | $874.00M | $934.00M | $866.00M | $808.00M | $825.00M | $828.00M | $756.00M |
EBITDA | $2.91B | $2.64B | $2.34B | $2.87B | $2.59B | $2.48B | $2.44B | $2.28B | $2.69B | $3.30B | $3.83B | $3.84B | $3.46B | $2.83B | $3.11B | $3.55B | $2.25B | $1.55B | $1.63B | $2.27B |
EBITDA Ratio | 27.33% | 16.60% | 14.55% | 26.14% | 25.56% | 24.68% | 25.48% | 22.60% | 22.68% | 29.37% | 29.44% | 25.77% | 28.73% | 19.32% | 25.62% | 28.20% | 23.17% | 16.42% | 17.09% | 23.13% |
Operating Income | $1.86B | $1.72B | $1.45B | $1.86B | $1.77B | $1.66B | $1.68B | $1.30B | $1.77B | $2.38B | $2.91B | $2.38B | $2.55B | $1.39B | $2.11B | $2.43B | $1.50B | $672.00M | $758.00M | $1.39B |
Operating Income Ratio | 17.48% | 16.60% | 14.55% | 18.20% | 17.44% | 16.67% | 17.22% | 12.92% | 17.00% | 21.11% | 24.48% | 20.74% | 23.30% | 13.62% | 20.17% | 22.73% | 16.89% | 9.17% | 9.81% | 16.71% |
Total Other Income Expenses Net | $81.00M | $-62.00M | $50.00M | $427.00M | $24.00M | $94.00M | $53.00M | $16.00M | $-12.00M | $-24.00M | $-36.00M | $-51.00M | $-53.00M | $-44.00M | $-66.00M | $-44.00M | $-74.00M | $-146.00M | $-125.00M | $-149.00M |
Income Before Tax | $1.94B | $1.61B | $1.44B | $1.79B | $1.67B | $1.64B | $1.56B | $1.32B | $1.76B | $2.35B | $2.88B | $2.33B | $2.49B | $1.35B | $2.04B | $2.39B | $1.42B | $526.00M | $633.00M | $1.24B |
Income Before Tax Ratio | 18.24% | 15.49% | 14.41% | 17.53% | 16.47% | 16.40% | 16.03% | 13.08% | 16.89% | 20.89% | 24.18% | 20.29% | 22.81% | 13.19% | 19.54% | 22.32% | 16.05% | 7.18% | 8.19% | 14.91% |
Income Tax Expense | $294.00M | $305.00M | $211.00M | $201.00M | $235.00M | $261.00M | $244.00M | $287.00M | $323.00M | $334.00M | $429.00M | $338.00M | $393.00M | $159.00M | $250.00M | $230.00M | $189.00M | $-11.00M | $89.00M | $191.00M |
Net Income | $1.65B | $1.30B | $1.23B | $1.59B | $1.44B | $1.38B | $1.32B | $1.03B | $1.44B | $2.02B | $2.45B | $1.99B | $2.10B | $1.19B | $1.79B | $2.16B | $1.23B | $537.00M | $564.00M | $1.05B |
Net Income Ratio | 15.48% | 12.55% | 12.29% | 15.56% | 14.16% | 13.78% | 13.52% | 10.24% | 13.78% | 17.93% | 20.57% | 17.34% | 19.22% | 11.63% | 17.15% | 20.20% | 13.92% | 7.33% | 7.30% | 12.62% |
EPS | $0.95 | $0.75 | $0.71 | $0.92 | $0.83 | $0.79 | $0.76 | $0.59 | $0.82 | $1.15 | $1.40 | $1.13 | $1.19 | $0.67 | $1.01 | $1.22 | $0.70 | $0.30 | $0.32 | $0.60 |
EPS Diluted | $0.94 | $0.74 | $0.70 | $0.91 | $0.82 | $0.78 | $0.75 | $0.59 | $0.81 | $1.14 | $1.38 | $1.12 | $1.17 | $0.66 | $1.00 | $1.21 | $0.69 | $0.30 | $0.32 | $0.59 |
Weighted Average Shares Outstanding | 1.73B | 1.73B | 1.73B | 1.73B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.75B | 1.75B | 1.76B | 1.77B | 1.77B | 1.78B | 1.77B | 1.77B | 1.77B | 1.77B | 1.76B |
Weighted Average Shares Outstanding Diluted | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.76B | 1.76B | 1.77B | 1.78B | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B | 1.78B | 1.78B | 1.78B |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $6.90B | $9.88B | $9.80B | $6.84B | $3.86B |
Short Term Investments | $383.00M | $288.00M | $450.00M | $310.00M | $280.00M |
Cash and Short Term Investments | $7.28B | $10.17B | $10.25B | $7.15B | $4.14B |
Net Receivables | $6.57B | $6.22B | $6.49B | $6.41B | $5.42B |
Inventory | $6.57B | $6.17B | $5.16B | $5.01B | $4.32B |
Other Current Assets | $2.26B | $2.66B | $2.35B | $1.87B | $1.79B |
Total Current Assets | $22.67B | $25.22B | $24.24B | $20.44B | $15.67B |
Property Plant Equipment Net | $11.28B | $9.16B | $8.96B | $9.03B | $8.04B |
Goodwill | $23.68B | $22.80B | $23.23B | $23.74B | $23.20B |
Intangible Assets | $8.81B | $10.45B | $12.74B | $14.78B | $17.02B |
Goodwill and Intangible Assets | $32.49B | $33.25B | $35.97B | $38.53B | $40.22B |
Long Term Investments | $799.00M | $766.00M | $816.00M | $821.00M | $883.00M |
Tax Assets | $- | $6.03B | $5.21B | $3.73B | $3.08B |
Other Non-Current Assets | $5.97B | $- | $- | $- | $- |
Total Non-Current Assets | $50.54B | $49.21B | $50.96B | $52.11B | $52.22B |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $73.21B | $74.44B | $75.20B | $72.55B | $67.89B |
Account Payables | $4.29B | $4.61B | $4.41B | $3.95B | $3.25B |
Short Term Debt | $1.32B | $2.48B | $999.00M | $461.00M | $1.68B |
Tax Payables | $492.00M | $343.00M | $306.00M | $362.00M | $226.00M |
Deferred Revenue | $174.00M | $- | $- | $- | $- |
Other Current Liabilities | $7.55B | $8.06B | $7.39B | $7.14B | $5.70B |
Total Current Liabilities | $13.84B | $15.49B | $13.11B | $11.91B | $10.86B |
Long Term Debt | $14.55B | $15.46B | $18.25B | $19.43B | $17.42B |
Deferred Revenue Non-Current | $- | $- | $2.74B | $3.12B | $2.82B |
Deferred Tax Liabilities Non-Current | $- | $991.00M | $1.39B | $1.41B | $1.55B |
Other Non-Current Liabilities | $6.00B | $4.74B | $5.74B | $6.06B | $6.18B |
Total Non-Current Liabilities | $20.55B | $22.04B | $26.07B | $27.64B | $25.72B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $34.39B | $37.53B | $39.17B | $39.55B | $36.59B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $24.87B | $24.71B | $24.47B | $24.14B | $23.85B |
Retained Earnings | $37.55B | $35.26B | $31.53B | $27.63B | $25.85B |
Accumulated Other Comprehensive Income Loss | $-7.84B | $-8.05B | $-8.37B | $-8.95B | $-8.46B |
Other Total Stockholders Equity | $-15.98B | $-15.23B | $-11.82B | $-10.04B | $-10.15B |
Total Stockholders Equity | $38.60B | $36.69B | $35.80B | $32.78B | $31.09B |
Total Equity | $38.83B | $36.91B | $36.02B | $33.00B | $31.30B |
Total Liabilities and Stockholders Equity | $73.21B | $74.44B | $75.20B | $72.55B | $67.89B |
Minority Interest | $224.00M | $219.00M | $222.00M | $219.00M | $213.00M |
Total Liabilities and Total Equity | $73.21B | $74.44B | $75.20B | $72.55B | $67.89B |
Total Investments | $1.18B | $1.05B | $1.27B | $1.13B | $1.16B |
Total Debt | $15.87B | $17.72B | $19.01B | $19.65B | $18.89B |
Net Debt | $8.98B | $7.83B | $9.21B | $12.81B | $15.03B |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $7.56B | $6.99B | $6.28B | $6.90B | $6.71B | $7.83B | $9.88B | $9.88B | $9.59B | $8.94B | $7.67B | $9.80B | $9.30B | $8.66B | $8.05B | $6.84B | $4.48B | $4.76B | $3.38B | $3.86B |
Short Term Investments | $230.00M | $232.00M | $367.00M | $383.00M | $338.00M | $320.00M | $288.00M | $288.00M | $313.00M | $353.00M | $483.00M | $450.00M | $390.00M | $286.00M | $318.00M | $310.00M | $251.00M | $274.00M | $291.00M | $280.00M |
Cash and Short Term Investments | $7.79B | $7.22B | $6.65B | $7.28B | $7.05B | $8.15B | $10.17B | $10.17B | $9.91B | $9.29B | $8.16B | $10.25B | $9.69B | $8.94B | $8.37B | $7.15B | $4.73B | $5.04B | $3.67B | $4.14B |
Net Receivables | $9.20B | $6.85B | $6.61B | $6.57B | $6.50B | $6.17B | $6.02B | $8.88B | $6.41B | $7.20B | $7.18B | $6.49B | $6.41B | $6.11B | $6.10B | $6.41B | $5.65B | $5.14B | $5.29B | $5.42B |
Inventory | $6.81B | $6.81B | $6.83B | $6.57B | $6.65B | $6.87B | $6.17B | $6.17B | $5.73B | $5.90B | $5.69B | $5.16B | $5.26B | $5.44B | $5.39B | $5.01B | $5.15B | $5.20B | $4.57B | $4.32B |
Other Current Assets | $- | $4.25B | $4.42B | $4.34B | $2.47B | $2.31B | $2.15B | $- | $2.80B | $2.57B | $2.40B | $2.35B | $2.13B | $2.13B | $1.96B | $1.87B | $1.86B | $1.84B | $1.97B | $1.79B |
Total Current Assets | $23.80B | $23.12B | $22.38B | $22.67B | $22.66B | $23.50B | $25.22B | $25.22B | $24.84B | $24.96B | $23.43B | $24.24B | $23.49B | $22.63B | $21.82B | $20.44B | $17.39B | $17.22B | $15.50B | $15.67B |
Property Plant Equipment Net | $10.62B | $10.23B | $10.11B | $11.28B | $9.55B | $9.45B | $9.16B | $9.16B | $8.69B | $8.82B | $8.91B | $8.96B | $8.83B | $8.82B | $8.83B | $9.03B | $8.62B | $8.34B | $7.91B | $8.04B |
Goodwill | $23.66B | $23.31B | $23.38B | $23.68B | $23.28B | $23.26B | $22.80B | $22.80B | $22.28B | $22.74B | $23.18B | $23.23B | $23.30B | $23.48B | $23.38B | $23.74B | $23.34B | $23.08B | $22.93B | $23.20B |
Intangible Assets | $7.35B | $7.83B | $8.30B | $8.81B | $9.28B | $9.83B | $10.45B | $10.45B | $10.85B | $11.59B | $12.22B | $12.74B | $13.31B | $13.68B | $14.18B | $14.78B | $15.21B | $15.80B | $16.20B | $17.02B |
Goodwill and Intangible Assets | $31.01B | $31.14B | $31.68B | $32.49B | $32.56B | $33.09B | $33.25B | $33.25B | $33.13B | $34.34B | $35.40B | $35.97B | $36.61B | $37.17B | $37.56B | $38.53B | $38.55B | $38.88B | $39.13B | $40.22B |
Long Term Investments | $912.00M | $877.00M | $818.00M | $799.00M | $788.00M | $799.00M | $766.00M | $766.00M | $764.00M | $734.00M | $763.00M | $816.00M | $812.00M | $805.00M | $832.00M | $821.00M | $803.00M | $776.00M | $790.00M | $883.00M |
Tax Assets | $- | $7.65B | $7.49B | $- | $6.53B | $6.51B | $6.03B | $6.03B | $5.37B | $5.36B | $5.50B | $5.21B | $4.05B | $3.85B | $3.74B | $3.73B | $3.68B | $3.57B | $3.39B | $3.08B |
Other Non-Current Assets | $8.01B | $- | $- | $5.97B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Non-Current Assets | $50.55B | $49.90B | $50.09B | $50.54B | $49.43B | $49.85B | $49.21B | $49.21B | $47.96B | $49.25B | $50.58B | $50.96B | $50.30B | $50.64B | $50.97B | $52.11B | $51.65B | $51.57B | $51.21B | $52.22B |
Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $74.36B | $73.02B | $72.47B | $73.21B | $72.09B | $73.35B | $74.44B | $74.44B | $72.80B | $74.20B | $74.01B | $75.20B | $73.80B | $73.27B | $72.78B | $72.55B | $69.04B | $68.79B | $66.71B | $67.89B |
Account Payables | $4.03B | $4.12B | $4.18B | $4.29B | $3.96B | $4.21B | $4.17B | $4.61B | $4.13B | $4.49B | $4.76B | $4.41B | $4.02B | $4.02B | $4.07B | $3.95B | $3.19B | $3.33B | $3.18B | $3.25B |
Short Term Debt | $2.15B | $1.61B | $2.01B | $1.08B | $1.05B | $2.28B | $2.29B | $2.25B | $1.12B | $5.00M | $4.00M | $999.00M | $951.00M | $954.00M | $955.00M | $461.00M | $214.00M | $1.50B | $1.47B | $1.68B |
Tax Payables | $713.00M | $601.00M | $562.00M | $492.00M | $318.00M | $273.00M | $343.00M | $343.00M | $394.00M | $355.00M | $338.00M | $306.00M | $368.00M | $242.00M | $276.00M | $362.00M | $117.00M | $165.00M | $165.00M | $226.00M |
Deferred Revenue | $- | $601.00M | $562.00M | $1.45B | $318.00M | $273.00M | $- | $- | $- | $- | $- | $- | $368.00M | $242.00M | $276.00M | $362.00M | $117.00M | $165.00M | $165.00M | $226.00M |
Other Current Liabilities | $8.00B | $7.42B | $6.71B | $7.97B | $7.71B | $7.58B | $7.74B | $8.29B | $7.72B | $7.54B | $7.55B | $7.39B | $7.53B | $7.40B | $7.17B | $7.14B | $6.74B | $5.96B | $5.99B | $5.70B |
Total Current Liabilities | $14.90B | $13.76B | $14.02B | $13.84B | $13.04B | $14.35B | $15.49B | $15.49B | $13.37B | $12.39B | $12.65B | $13.11B | $12.87B | $12.61B | $12.46B | $11.91B | $10.26B | $10.96B | $10.81B | $10.86B |
Long Term Debt | $12.82B | $13.14B | $12.58B | $14.55B | $14.48B | $14.56B | $14.62B | $15.46B | $15.30B | $16.75B | $17.09B | $18.25B | $17.45B | $17.55B | $17.49B | $19.43B | $18.35B | $18.18B | $16.80B | $17.42B |
Deferred Revenue Non-Current | $- | $-6.56B | $-6.83B | $949.00M | $-6.88B | $-7.04B | $-7.42B | $- | $-8.26B | $-8.34B | $- | $- | $- | $- | $- | $- | $- | $-8.84B | $-8.74B | $- |
Deferred Tax Liabilities Non-Current | $- | $6.56B | $6.83B | $1.22B | $6.88B | $7.04B | $7.52B | $991.00M | $8.26B | $8.34B | $- | $1.39B | $- | $- | $- | $1.41B | $- | $8.84B | $8.74B | $1.55B |
Other Non-Current Liabilities | $6.60B | $6.56B | $6.83B | $4.78B | $6.88B | $7.04B | $7.42B | $5.59B | $8.26B | $8.34B | $8.64B | $5.74B | $8.84B | $9.08B | $9.05B | $6.06B | $8.84B | $8.84B | $8.74B | $6.18B |
Total Non-Current Liabilities | $19.43B | $19.70B | $19.40B | $20.55B | $21.35B | $21.60B | $22.04B | $22.04B | $23.55B | $25.09B | $25.73B | $26.07B | $26.29B | $26.63B | $26.54B | $27.64B | $27.19B | $27.02B | $25.54B | $25.72B |
Other Liabilities | $- | $- | $- | $- | $- | $- | $-971.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $34.33B | $33.46B | $33.42B | $34.39B | $34.40B | $35.95B | $36.56B | $37.53B | $36.92B | $37.49B | $38.38B | $39.17B | $39.16B | $39.24B | $39.00B | $39.55B | $37.45B | $37.98B | $36.35B | $36.59B |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $25.02B | $24.86B | $24.73B | $24.87B | $24.73B | $24.61B | $24.71B | $24.71B | $24.56B | $24.43B | $24.30B | $24.47B | $24.29B | $24.15B | $24.02B | $24.14B | $24.04B | $23.89B | $23.73B | $23.85B |
Retained Earnings | $39.06B | $38.35B | $38.01B | $37.55B | $36.92B | $36.35B | $35.87B | $35.26B | $35.12B | $34.49B | $33.30B | $31.53B | $30.38B | $29.05B | $28.67B | $27.63B | $26.27B | $25.67B | $25.79B | $25.85B |
Accumulated Other Comprehensive Income Loss | $-7.80B | $-8.13B | $-8.17B | $-7.84B | $-8.48B | $-8.07B | $-8.05B | $-8.05B | $-9.45B | $-8.71B | $-8.47B | $-8.37B | $-9.24B | $-9.07B | $-9.29B | $-8.95B | $-9.04B | $-9.08B | $-9.39B | $-8.46B |
Other Total Stockholders Equity | $-16.48B | $-15.76B | $-15.76B | $-15.98B | $-15.69B | $-15.72B | $-15.31B | $-15.23B | $-14.55B | $-13.72B | $-13.73B | $-11.82B | $-11.00B | $-10.34B | $-9.85B | $-10.04B | $-9.87B | $-9.90B | $-9.91B | $-10.15B |
Total Stockholders Equity | $39.80B | $39.32B | $38.81B | $38.60B | $37.48B | $37.17B | $74.22B | $36.69B | $35.67B | $36.49B | $35.40B | $35.80B | $34.42B | $33.80B | $33.56B | $32.78B | $31.39B | $30.58B | $30.22B | $31.09B |
Total Equity | $40.03B | $39.56B | $39.04B | $38.83B | $37.69B | $37.40B | $74.44B | $36.91B | $35.88B | $36.72B | $35.63B | $36.02B | $34.64B | $34.03B | $33.79B | $33.00B | $31.59B | $30.80B | $30.43B | $31.30B |
Total Liabilities and Stockholders Equity | $74.36B | $73.02B | $72.47B | $73.21B | $72.09B | $73.35B | $74.44B | $74.44B | $72.80B | $74.20B | $74.01B | $75.20B | $73.80B | $73.27B | $72.78B | $72.55B | $69.04B | $68.78B | $66.78B | $67.89B |
Minority Interest | $232.00M | $242.00M | $233.00M | $224.00M | $213.00M | $230.00M | $222.00M | $219.00M | $209.00M | $226.00M | $230.00M | $222.00M | $216.00M | $229.00M | $226.00M | $219.00M | $209.00M | $220.00M | $209.00M | $213.00M |
Total Liabilities and Total Equity | $74.36B | $73.02B | $72.47B | $73.21B | $72.09B | $73.35B | $74.44B | $74.44B | $72.80B | $74.20B | $74.01B | $75.20B | $73.80B | $73.27B | $72.78B | $72.55B | $69.04B | $68.78B | $66.78B | $67.89B |
Total Investments | $1.14B | $1.11B | $1.19B | $1.18B | $1.13B | $1.12B | $1.05B | $1.05B | $1.08B | $784.00M | $1.25B | $1.27B | $1.20B | $1.09B | $1.15B | $1.13B | $1.05B | $1.05B | $1.08B | $1.16B |
Total Debt | $14.98B | $14.75B | $14.59B | $15.87B | $15.53B | $16.85B | $16.77B | $17.72B | $16.41B | $16.76B | $17.09B | $19.01B | $18.40B | $18.50B | $18.44B | $19.65B | $18.56B | $19.68B | $18.27B | $18.89B |
Net Debt | $7.42B | $7.77B | $8.30B | $8.98B | $8.82B | $9.01B | $6.89B | $7.83B | $6.82B | $7.82B | $9.41B | $9.21B | $9.10B | $9.84B | $10.39B | $12.81B | $14.08B | $14.92B | $14.89B | $15.03B |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B |
Depreciation and Amortization | $3.24B | $3.27B | $3.54B | $3.33B | $3.01B |
Deferred Income Tax | $- | $- | $- | $- | $- |
Stock Based Compensation | $644.00M | $685.00M | $640.00M | $546.00M | $519.00M |
Change in Working Capital | $-2.48B | $-1.52B | $-771.00M | $-892.00M | $-1.33B |
Accounts Receivables | $-356.00M | $-68.00M | $-383.00M | $-924.00M | $-275.00M |
Inventory | $-232.00M | $-1.41B | $-456.00M | $-493.00M | $-593.00M |
Accounts Payables | $-760.00M | $420.00M | $1.29B | $1.77B | $220.00M |
Other Working Capital | $-1.13B | $-458.00M | $-1.22B | $-1.24B | $-683.00M |
Other Non Cash Items | $126.00M | $215.00M | $55.00M | $425.00M | $247.00M |
Net Cash Provided by Operating Activities | $7.26B | $9.58B | $10.53B | $7.90B | $6.14B |
Investments in Property Plant and Equipment | $-2.20B | $-1.78B | $-1.89B | $-2.18B | $-1.64B |
Acquisitions Net | $-837.00M | $48.00M | $-53.00M | $16.00M | $-122.00M |
Purchases of Investments | $-159.00M | $-185.00M | $-173.00M | $-83.00M | $-103.00M |
Sales Maturities of Investments | $43.00M | $152.00M | $77.00M | $10.00M | $21.00M |
Other Investing Activities | $22.00M | $22.00M | $26.00M | $19.00M | $27.00M |
Net Cash Used for Investing Activities | $-3.13B | $-1.74B | $-2.01B | $-2.21B | $-1.81B |
Debt Repayment | $-2.48B | $-699.00M | $-248.00M | $-50.00M | $-1.60B |
Common Stock Issued | $- | $- | $- | $- | $- |
Common Stock Repurchased | $-1.23B | $-3.79B | $-2.30B | $-403.00M | $-718.00M |
Dividends Paid | $-3.56B | $-3.31B | $-3.20B | $-2.56B | $-2.27B |
Other Financing Activities | $167.00M | $167.00M | $255.00M | $234.00M | $298.00M |
Net Cash Used Provided by Financing Activities | $-7.09B | $-7.64B | $-5.49B | $-2.78B | $-4.29B |
Effect of Forex Changes on Cash | $-23.00M | $-122.00M | $-70.00M | $71.00M | $-16.00M |
Net Change in Cash | $-2.99B | $83.00M | $2.96B | $2.98B | $16.00M |
Cash at End of Period | $6.90B | $9.88B | $9.80B | $6.84B | $3.86B |
Cash at Beginning of Period | $9.88B | $9.80B | $6.84B | $3.86B | $3.84B |
Operating Cash Flow | $7.26B | $9.58B | $10.53B | $7.90B | $6.14B |
Capital Expenditure | $-2.20B | $-1.78B | $-1.89B | $-2.18B | $-1.64B |
Free Cash Flow | $5.06B | $7.80B | $8.65B | $5.72B | $4.50B |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $1.64B | $1.30B | $1.22B | $1.59B | $1.44B | $1.38B | $1.32B | $1.03B | $1.44B | $2.02B | $2.45B | $1.99B | $2.10B | $1.19B | $1.79B | $2.16B | $1.23B | $537.00M | $564.00M | $1.05B |
Depreciation and Amortization | $801.00M | $805.00M | $805.00M | $813.00M | $824.00M | $800.00M | $806.00M | $807.00M | $815.00M | $822.00M | $823.00M | $883.00M | $847.00M | $874.00M | $934.00M | $866.00M | $808.00M | $825.00M | $828.00M | $756.00M |
Deferred Income Tax | $- | $- | $- | $-1.38B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Stock Based Compensation | $117.00M | $141.00M | $304.00M | $114.00M | $117.00M | $132.00M | $281.00M | $115.00M | $123.00M | $142.00M | $305.00M | $106.00M | $114.00M | $132.00M | $288.00M | $98.00M | $100.00M | $115.00M | $233.00M | $85.00M |
Change in Working Capital | $141.00M | $-288.00M | $-1.31B | $391.00M | $-321.00M | $-444.00M | $-186.00M | $114.00M | $336.00M | $-664.00M | $-1.30B | $-106.00M | $-323.00M | $30.00M | $-372.00M | $289.00M | $-321.00M | $-319.00M | $-541.00M | $-244.00M |
Accounts Receivables | $- | $-325.00M | $-151.00M | $68.00M | $-461.00M | $-196.00M | $233.00M | $341.00M | $530.00M | $-188.00M | $-751.00M | $-189.00M | $-394.00M | $35.00M | $165.00M | $-581.00M | $-470.00M | $231.00M | $-104.00M | $82.00M |
Inventory | $220.00M | $-103.00M | $-410.00M | $295.00M | $140.00M | $-248.00M | $-419.00M | $-189.00M | $-194.00M | $-476.00M | $-554.00M | $15.00M | $71.00M | $-5.00M | $-537.00M | $345.00M | $149.00M | $-550.00M | $-437.00M | $137.00M |
Accounts Payables | $- | $- | $- | $-1.34B | $179.00M | $660.00M | $- | $- | $-71.00M | $- | $- | $1.29B | $- | $- | $-9.36B | $1.77B | $-7.13B | $-6.26B | $-4.69B | $220.00M |
Other Working Capital | $-79.00M | $140.00M | $-748.00M | $1.37B | $-179.00M | $-660.00M | $186.00M | $-38.00M | $71.00M | $92.00M | $-205.00M | $-1.22B | $-37.00M | $-97.00M | $9.36B | $-1.24B | $7.13B | $6.26B | $4.69B | $-683.00M |
Other Non Cash Items | $6.00M | $2.18B | $2.48B | $1.51B | $-179.00M | $-660.00M | $-1.08B | $257.00M | $71.00M | $92.00M | $-205.00M | $195.00M | $-37.00M | $-97.00M | $-6.00M | $383.00M | $247.00M | $164.00M | $-369.00M | $770.00M |
Net Cash Provided by Operating Activities | $2.71B | $1.96B | $1.02B | $3.04B | $1.88B | $1.20B | $1.14B | $2.33B | $2.78B | $2.41B | $2.06B | $3.07B | $2.70B | $2.13B | $2.64B | $3.80B | $2.07B | $1.32B | $715.00M | $2.42B |
Investments in Property Plant and Equipment | $- | $-533.00M | $-398.00M | $-755.00M | $-560.00M | $-507.00M | $-380.00M | $-610.00M | $-467.00M | $-379.00M | $-321.00M | $-614.00M | $-461.00M | $-413.00M | $-397.00M | $-679.00M | $-496.00M | $-642.00M | $-360.00M | $-434.00M |
Acquisitions Net | $-1.00M | $1.00M | $- | $-40.00M | $-51.00M | $-786.00M | $- | $- | $- | $48.00M | $- | $-134.00M | $-86.00M | $48.00M | $-15.00M | $-58.00M | $- | $16.00M | $- | $1.00M |
Purchases of Investments | $9.00M | $28.00M | $-28.00M | $-114.00M | $-38.00M | $79.00M | $-86.00M | $- | $-3.00M | $41.00M | $-41.00M | $-173.00M | $-27.00M | $14.00M | $-14.00M | $-83.00M | $- | $- | $-36.00M | $-103.00M |
Sales Maturities of Investments | $-40.00M | $49.00M | $- | $43.00M | $38.00M | $707.00M | $- | $- | $- | $- | $- | $77.00M | $-81.00M | $81.00M | $- | $10.00M | $- | $- | $- | $21.00M |
Other Investing Activities | $-562.00M | $2.00M | $1.00M | $2.00M | $-23.00M | $-706.00M | $4.00M | $-22.00M | $-14.00M | $8.00M | $2.00M | $173.00M | $-104.00M | $101.00M | $4.00M | $79.00M | $24.00M | $7.00M | $3.00M | $26.00M |
Net Cash Used for Investing Activities | $-594.00M | $-453.00M | $-425.00M | $-824.00M | $-634.00M | $-1.21B | $-462.00M | $-632.00M | $-484.00M | $-264.00M | $-360.00M | $-671.00M | $-651.00M | $-264.00M | $-422.00M | $-731.00M | $-472.00M | $-619.00M | $-393.00M | $-489.00M |
Debt Repayment | $43.00M | $160.00M | $-127.00M | $-939.00M | $-1.51B | $12.00M | $-42.00M | $10.00M | $24.00M | $10.00M | $-743.00M | $-196.00M | $-67.00M | $-7.00M | $22.00M | $-1.00M | $-1.36B | $1.26B | $50.00M | $-1.13B |
Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock Repurchased | $-751.00M | $-3.00M | $-226.00M | $-259.00M | $-2.00M | $-426.00M | $-540.00M | $-685.00M | $-798.00M | $-5.00M | $-2.31B | $-974.00M | $-579.00M | $-471.00M | $-275.00M | $-161.00M | $-2.00M | $-4.00M | $-236.00M | $-496.00M |
Dividends Paid | $-960.00M | $-961.00M | $-957.00M | $-888.00M | $-888.00M | $-890.00M | $-890.00M | $-823.00M | $-826.00M | $-828.00M | $-832.00M | $-798.00M | $-801.00M | $-803.00M | $-800.00M | $-641.00M | $-639.00M | $-642.00M | $-638.00M | $-568.00M |
Other Financing Activities | $92.00M | $13.00M | $134.00M | $34.00M | $56.00M | $15.00M | $62.00M | $41.00M | $57.00M | $10.00M | $59.00M | $82.00M | $70.00M | $17.00M | $86.00M | $16.00M | $83.00M | $46.00M | $89.00M | $7.00M |
Net Cash Used Provided by Financing Activities | $-1.58B | $-791.00M | $-1.18B | $-2.05B | $-2.34B | $-1.29B | $-1.41B | $-1.46B | $-1.54B | $-813.00M | $-3.82B | $-1.89B | $-1.38B | $-1.26B | $-967.00M | $-787.00M | $-1.92B | $658.00M | $-735.00M | $-2.19B |
Effect of Forex Changes on Cash | $36.00M | $-13.00M | $-36.00M | $25.00M | $-29.00M | $-27.00M | $8.00M | $51.00M | $-96.00M | $-71.00M | $-6.00M | $-13.00M | $-29.00M | $4.00M | $-32.00M | $78.00M | $38.00M | $25.00M | $-70.00M | $27.00M |
Net Change in Cash | $571.00M | $703.00M | $-612.00M | $187.00M | $-1.13B | $-1.33B | $-721.00M | $288.00M | $657.00M | $1.26B | $-2.12B | $497.00M | $644.00M | $604.00M | $1.22B | $2.36B | $-283.00M | $1.39B | $-483.00M | $-231.00M |
Cash at End of Period | $7.56B | $6.99B | $6.28B | $6.90B | $6.71B | $7.83B | $9.16B | $9.88B | $9.59B | $8.94B | $7.67B | $9.80B | $9.30B | $8.66B | $8.05B | $6.84B | $4.48B | $4.76B | $3.38B | $3.86B |
Cash at Beginning of Period | $6.99B | $6.28B | $6.90B | $6.71B | $7.83B | $9.16B | $9.88B | $9.59B | $8.94B | $7.67B | $9.80B | $9.30B | $8.66B | $8.05B | $6.84B | $4.48B | $4.76B | $3.38B | $3.86B | $4.09B |
Operating Cash Flow | $2.71B | $1.96B | $1.02B | $3.04B | $1.88B | $1.20B | $1.14B | $2.33B | $2.78B | $2.41B | $2.06B | $3.07B | $2.70B | $2.13B | $2.64B | $3.80B | $2.07B | $1.32B | $715.00M | $2.42B |
Capital Expenditure | $-556.00M | $-533.00M | $-398.00M | $-755.00M | $-560.00M | $-507.00M | $-380.00M | $-610.00M | $-467.00M | $-379.00M | $-321.00M | $-614.00M | $-461.00M | $-413.00M | $-397.00M | $-679.00M | $-496.00M | $-642.00M | $-360.00M | $-434.00M |
Free Cash Flow | $2.15B | $1.43B | $627.00M | $2.28B | $1.32B | $696.00M | $763.00M | $1.72B | $2.31B | $2.03B | $1.74B | $2.45B | $2.24B | $1.72B | $2.24B | $3.12B | $1.57B | $680.00M | $355.00M | $1.98B |
Abbott Laboratories Stock Forecast
Analyst ratings, price targets, and earnings estimates for ABT.
ABT Analyst Ratings
Strong Buy
Based on 17 analysts in the past 3 months
ABT Stock 12 Month Forecast
$135.00
Based on 1 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Jan 08, 2025 | Lee Hambright | Bernstein | $135.00 | $114.25 | 18.2% |
Oct 17, 2024 | Adam Maeder | Piper Sandler | $133.00 | $117.82 | 12.9% |
Oct 17, 2024 | Lee Hambright | Bernstein | $138.00 | $117.82 | 17.1% |
Oct 16, 2024 | Matthew Taylor | Jefferies | $125.00 | $117.82 | 6.1% |
Oct 16, 2024 | Vijay Kumar | Evercore ISI | $128.00 | $117.82 | 8.6% |
Oct 16, 2024 | Marie Thibault | BTIG | $139.00 | $117.82 | 18.0% |
Oct 08, 2024 | Charles Minervino | Susquehanna | $120.00 | $114.30 | 5.0% |
Oct 08, 2024 | Suraj Kalia | Oppenheimer | $130.00 | $114.30 | 13.7% |
Oct 08, 2024 | Shagun Singh | RBC Capital | $130.00 | $113.36 | 14.7% |
Sep 19, 2024 | Jonathan Atkin | RBC Capital | $345.00 | $54.49 | 533.1% |
Abbott Laboratories Dividends
Explore Abbott Laboratories's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.86%
Dividend Payout Ratio
62.14%
Dividend Paid & Capex Coverage Ratio
1.26x
Abbott Laboratories Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$0.59 | $0.59 | January 15, 2025 | January 15, 2025 | February 14, 2025 | December 13, 2024 |
$0.55 | $0.55 | October 15, 2024 | October 15, 2024 | November 15, 2024 | September 19, 2024 |
$0.55 | $0.55 | July 15, 2024 | July 15, 2024 | August 15, 2024 | June 14, 2024 |
$0.55 | $0.55 | April 12, 2024 | April 15, 2024 | May 15, 2024 | February 16, 2024 |
$0.55 | $0.55 | January 11, 2024 | January 12, 2024 | February 15, 2024 | December 15, 2023 |
$0.51 | $0.51 | October 12, 2023 | October 13, 2023 | November 15, 2023 | September 21, 2023 |
$0.51 | $0.51 | July 13, 2023 | July 14, 2023 | August 15, 2023 | June 09, 2023 |
$0.51 | $0.51 | April 13, 2023 | April 14, 2023 | May 15, 2023 | February 17, 2023 |
$0.51 | $0.51 | January 12, 2023 | January 13, 2023 | February 15, 2023 | December 09, 2022 |
$0.47 | $0.47 | October 13, 2022 | October 14, 2022 | November 15, 2022 | September 15, 2022 |
$0.47 | $0.47 | July 14, 2022 | July 15, 2022 | August 15, 2022 | June 10, 2022 |
$0.47 | $0.47 | April 13, 2022 | April 15, 2022 | May 16, 2022 | February 18, 2022 |
$0.47 | $0.47 | January 13, 2022 | January 14, 2022 | February 15, 2022 | December 10, 2021 |
$0.45 | $0.45 | October 14, 2021 | October 15, 2021 | November 15, 2021 | September 15, 2021 |
$0.45 | $0.45 | July 14, 2021 | July 15, 2021 | August 16, 2021 | June 11, 2021 |
$0.45 | $0.45 | April 14, 2021 | April 15, 2021 | May 17, 2021 | February 19, 2021 |
$0.45 | $0.45 | January 14, 2021 | January 15, 2021 | February 16, 2021 | December 11, 2020 |
$0.36 | $0.36 | October 14, 2020 | October 15, 2020 | November 16, 2020 | September 17, 2020 |
$0.36 | $0.36 | July 14, 2020 | July 15, 2020 | August 17, 2020 | June 12, 2020 |
$0.36 | $0.36 | April 14, 2020 | April 15, 2020 | May 15, 2020 | February 21, 2020 |
Peers: Medical - Devices
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() AbbVie Inc.
ABBV
|
$340.83B | $192.87 | $2.42 | $73.48 | $94.54 |
![]() Eli Lilly and Company
LLY
|
$801.48B | $844.27 | $11.71 | $65.93 | $48.75 |
![]() Bristol-Myers Squibb Company
BMY
|
$109.38B | $53.90 | $-4.41 | $-12.82 | $7.02 |
![]() Johnson & Johnson
JNJ
|
$375.95B | $156.15 | $5.84 | $24.53 | $27385.90 |
![]() Medtronic plc
MDT
|
$119.01B | $92.81 | $2.77 | $28.80 | $2.11 |
Related Metrics
Explore detailed financial metrics and analysis for ABT.